News & Updates
Filter by Specialty:
Early molnupiravir use benefits unvaccinated COVID-19 outpatients
Early administration (ie, within 5 days after symptom onset) of the oral, small-molecule antiviral prodrug molnupiravir slashed the risk of hospitalization or death in at-risk, unvaccinated, nonhospitalized adults with mild-to-moderate COVID-19, findings from the phase III component of the phase II/III MOVe-OUT trial have shown.
Early molnupiravir use benefits unvaccinated COVID-19 outpatients
18 Apr 2022
Obesity med cessation more likely after RYGB than sleeve gastrectomy
Patients who are on obesity-related medications before undergoing bariatric surgery may be more likely to discontinue their medications and less likely to restart them after undergoing Roux-en-Y gastric bypass (RYGB) than laparoscopic sleeve gastrectomy (LSG), a recent study has shown.
Obesity med cessation more likely after RYGB than sleeve gastrectomy
15 Apr 2022
Maintenance selinexor promising for PFS in advanced/recurrent endometrial cancer
Maintenance treatment with selinexor improved progression-free survival (PFS) in patients with advanced or recurrent endometrial cancer who had previously received first-line chemotherapy, particularly those with endometrioid histology and wild-type p53, according to a study presented at SGO 2022.
